Announced Mon, 6 Apr · 17:35 IST

In compliance with Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018; we furnish hereunder certificate dated 01st April,2026 received from the SEBI registered RTA ....

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
+3.3%1-day move
₹1710.00
prior close
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
+3.3+7.0+6.4+6.5+2.3+8.2+22.8+38.5+31.9+50.0
Up moveDown movePending
AI summary

Fredun Pharmaceuticals has submitted a routine quarterly compliance certificate to BSE under SEBI Regulation 74(5) for the quarter ended 31st March 2026. The certificate was issued by their Registrar and Transfer Agent, Purva Sharegistry (India) Pvt. Ltd., confirming that share certificates received for dematerialization during the quarter were properly processed, confirmed to the depositories, and the depositories' names were substituted in the register of members. Only two dematerialization requests were recorded during the quarter, totaling 1,000 shares (500 each from shareholders Nikhil Vora and Sheela Vora) on 9th February 2026.

Likely market impact

This is a routine regulatory compliance filing with no material impact on the stock or shareholders. It simply confirms that the company's share dematerialization process is functioning as required by SEBI regulations.